An advanced development offering that integrates formulation expertise with on-demand Phase 1 clinical manufacturing, adaptive clinical testing and regulatory support, to help achieve flexible and efficient First-in-Human studies and expedited development.
Summary: Experts provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon.
Summary: In this webinar, experts provide an overview of the needs of different patient populations and examine the common challenges leading to non-compliance.
Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.
This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.
Summary: Using Zydis® orally dissolving tablet (ODT) platform from Catalent as a unique delivery route for allergy immunotherapies.
